Hepatocellular Cancer clinical trials

Explore recruiting hepatocellular cancer clinical trials.

Recruiting hepatocellular cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatocellular Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter study

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CheckMate 9DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9DX)

France, Austria, Germany, Netherlands, Spain, Romania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Poland, Spain, Germany, Italy, Austria, France +1 more

Human Pharmacology (Phase I)- Other EU CTIS Study details

Hepatocellular Cancer trials by city

Hepatocellular Cancer clinical trials

Recruiting hepatocellular cancer studies right now

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Intravital Microscopy in Human Solid Tumors

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.